Arizona State University

University of Minnesota

Arizona Board of Regents, a Body Corporate

Finch Therapeutics Holdings LLC

Dae-Wook Kang

Rosa Krajmalnik-Brown

Joshua LaBaer

Jin Park

James Adams

Zehra Ilhan

Thomas Julius Borody

Michael J Sadowsky

Alexander Khoruts

Zehra IIhan

The present disclosure provides for characterization of normal flora and identifying biomarkers in the gut of healthy, neurotypical subjects. Aspect of the disclosure provide for the characterization of the gut microbiome in ADS subjects, characterized by reduced richness and significant loss of the '-like enterotype' compared to neurotypical subjects. The relative abundance of generaandare significantly lower in autistic children than in neurotypical children. Further,, is one of the three main classifiers for the human enterotypes, along with Bacteroides and. These three core genera are among main contributors in the principle component analysis. ‘-like enterotype’ was absent in the autistic group, while neurotypical samples showed an even distribution among the three enterotypes. The present disclosure provides for an understanding the association between gut microbiota, health, and disease states, and provides for potential diagnostic and therapeutic targets.

Microbiome markers and therapies for autism spectrum disorders

The present disclosure provides for characterization of normal flora and identifying biomarkers in the gut of healthy, neurotypical subjects. Aspect of the disclosure provide for the characterization of the gut microbiome in ADS subjects, characterized by reduced richness and significant loss of the '-like enterotype' compared to neurotypical subjects. The relative abundance of genera, Prevotellaceae and Veillonellaceae are significantly lower in autistic children than in neurotypical children. Further,is one of the three main classifiers for the human enterotypes, along withandThese three core genera are among main contributors in the principle component analysis. '-like enterotype' was absent in the autistic group, while neurotypical samples showed an even distribution among the three enterotypes. The present disclosure provides for an understanding the association between gut microbiota, health, and disease states, and provides for potential diagnostic and therapeutic targets.

The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for modulating the abundance of one or more gut microorganisms in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a fecal microbe preparation to achieve at least a 2-fold change of the abundance of said one or more fecal microorganisms, wherein said one or more gut microorganisms are selected from the group consisting of, and

Methods for treating autism spectrum disorder and associated symptoms

The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.

The present disclosure provides for characterization of normal flora and identifying biomarkers in the gut of healthy, neruotypical subjects. Aspect of the disclosure provide for the characterization of the gut microbiome in ADS subjects, characterized by reduced richness and significant loss of the '-like enterotype' compared to neurotypical subjects. The relative abundance of genera, Prevotellaceae and Veillonellaceae are significantly lower in autistic children than in neurotypical children. Further,, is one of the three main classifiers for the human enterotypes, along withand. These three core genera are among main contributors in the principle component analysis. '-like enterotype' was absent in the autistic group, while neurotypical samples showed an even distribution among the three enterotypes. The present disclosure provides for an understanding the association between gut microbiota, health, and disease states, and provides for potential diagnostic and therapeutic targets.

Growing community of inventors

Phoenix, AZ, United States of America

Dae-Wook Kang